ADA 2021 | SURPASS-2: Tirzepatide versus semaglutide in people with type 2 diabetes | diabetes.medicinematters.com

Register Login

Medicine Matters Diabetes

Javascript needed

Please enable JavaScript on your browser, so that you can use all features of this website.

window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'event': 'track', 'eventCategory': 'flash_warning', 'eventAction': 'Javascript needed', 'eventLabel': 'Please enable JavaScript on your browser, so that you can use all features of this website.' });

06-28-2021 | ADA 2021 | Conference coverage | Video

SURPASS-2: Tirzepatide versus semaglutide in people with type 2 diabetes

Juan Pablo Frías explains the significance of the SURPASS-2 findings, in which the dual agonist tirzepatide provided superior glycemic control and weight loss to semaglutide (5:44).

Medicine Matters Diabetes

SURPASS-2: Tirzepatide versus semaglutide in people with type 2 diabetes

Related content

SURPASS-1: Tirzepatide has ‘potent’ glucose-lowering and weight loss efficacy

SURPASS-3: Tirzepatide proves better option than degludec for type 2 diabetes

SURPASS-5: Glycemic, weight benefits of tirzepatide in insulin-dependent type 2 diabetes

A quick guide to the SURPASS and SURMOUNT trials

EASD Annual Meeting 2021 coverage

New additions to the Adis Journal Club

Medicine Matters Diabetes

SURPASS-2: Tirzepatide versus semaglutide in people with type 2 diabetes

External Content

Related content

SURPASS-1: Tirzepatide has ‘potent’ glucose-lowering and weight loss efficacy

SURPASS-3: Tirzepatide proves better option than degludec for type 2 diabetes

SURPASS-5: Glycemic, weight benefits of tirzepatide in insulin-dependent type 2 diabetes

A quick guide to the SURPASS and SURMOUNT trials

EASD Annual Meeting 2021 coverage

New additions to the Adis Journal Club